Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
Abstract: Based on the strong demand for independent control and the improvement of domestic databases, database localization has become an inevitable trend. In the process of migrating Oracle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results